Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Support > Literature Updates

Roads and detours for CAR T cell therapy in autoimmune diseases

Nature Reviews Drug Discovery volume 25, pages 290–309 (2026)

Chimeric antigen receptor (CAR) T cell therapy has been highly effective in eradicating malignant B cells in cancer, and this success has prompted an extension of the approach to areas beyond oncology. In pioneering studies, CAR T cells targeting the B cell marker CD19 demonstrated robust efficacy as treatment for the autoimmune disease systemic lupus erythematosus. Patients who received anti-CD19 CAR T cells experienced remission of most or all clinical manifestations and discontinued prior medications. These results have spurred intense interest in extending these observations to larger patient cohorts and other autoimmune conditions. More nuanced strategies for use of CARs in autoimmunity have also been developed. Here, we offer insight into the role of B cells in the pathophysiology of autoimmunity and present an overview of preclinical studies and clinical trials that use engineered cell therapy for autoimmune disorders.

Related products

Catalog No. Product Name Description Target
HB996012 Recombinant Human CD19 Protein Recombinant Human CD19 Protein, N-His (HB996012) expressed in E. coli, spanning Pro20-Lys291. Purity: >90% by SDS-PAGE. Highlights ●His-Tagged — N-terminal 6×His tag for IMAC purification. ●E. coli Expression — High-yield, cost-effective production. ●High Purity — >90% purity verified by SDS-PAGE.

Quick access

Contact Us

  • +86-27-87433958

  • info@abinscience.com

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only